Perjeta 420 MG/14 ML vial 14ML
Ended Awarded Last action
- Contract number
- SPE2DR26FHNS1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,906
Award facts
- Contract value 100% obligated
- $27,905.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $27,905.88 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order, issued on December 8, 2025, with an ultimate completion date of December 30, 2025, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded on November 13, 2025, that positions the company as a regional prime vendor contractor supporting the Department of Defense's global pharmaceutical supply chain.
The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to ensure reliable pharmaceutical sourcing for military healthcare facilities worldwide. DMS Pharmaceutical Group's role as a prime vendor contractor enables the Defense Logistics Agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, specialty pharmaceuticals, and medical consumables. The company's established performance across numerous delivery orders and its extensive product portfolio, spanning oncology treatments, immunosuppressants, emergency medications, and routine pharmaceuticals, demonstrates its capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system. No subcontractors were identified in this award documentation.
Quick answers
Who was awarded contract SPE2DR26FHNS1?
SPE2DR26FHNS1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FHNS1 worth?
The government has obligated $27,906 on SPE2DR26FHNS1.
Is contract SPE2DR26FHNS1 an order under another contract?
Yes. SPE2DR26FHNS1 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNS1 competed?
The extent of competition for SPE2DR26FHNS1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award